Taiwan
· Delayed Price · Currency is TWD Tanvex BioPharma Statistics
Total Valuation
TPE:6541 has a market cap or net worth of TWD 13.12 billion. The enterprise value is 13.81 billion.
| Market Cap | 13.12B |
| Enterprise Value | 13.81B |
Important Dates
The last earnings date was Wednesday, May 7, 2025.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TPE:6541 has 238.49 million shares outstanding. The number of shares has increased by 33.45% in one year.
| Current Share Class | 238.49M |
| Shares Outstanding | 238.49M |
| Shares Change (YoY) | +33.45% |
| Shares Change (QoQ) | +35.74% |
| Owned by Insiders (%) | 1.19% |
| Owned by Institutions (%) | 2.01% |
| Float | 100.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 161.57 |
| PB Ratio | 2.36 |
| P/TBV Ratio | 6.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.66 |
| EV / Sales | 170.06 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -11.27 |
Financial Position
The company has a current ratio of 2.89, with a Debt / Equity ratio of 0.32.
| Current Ratio | 2.89 |
| Quick Ratio | 2.21 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.44 |
| Interest Coverage | -25.80 |
Financial Efficiency
Return on equity (ROE) is -48.00% and return on invested capital (ROIC) is -16.89%.
| Return on Equity (ROE) | -48.00% |
| Return on Assets (ROA) | -15.97% |
| Return on Invested Capital (ROIC) | -16.89% |
| Return on Capital Employed (ROCE) | -18.65% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.51 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +27.91% in the last 52 weeks. The beta is 0.03, so TPE:6541's price volatility has been lower than the market average.
| Beta (5Y) | 0.03 |
| 52-Week Price Change | +27.91% |
| 50-Day Moving Average | 64.74 |
| 200-Day Moving Average | 65.01 |
| Relative Strength Index (RSI) | 36.14 |
| Average Volume (20 Days) | 212,688 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TPE:6541 had revenue of TWD 81.18 million and -1.43 billion in losses. Loss per share was -8.05.
| Revenue | 81.18M |
| Gross Profit | -14.41M |
| Operating Income | -1.33B |
| Pretax Income | -1.43B |
| Net Income | -1.43B |
| EBITDA | -1.20B |
| EBIT | -1.33B |
| Loss Per Share | -8.05 |
Balance Sheet
The company has 1.08 billion in cash and 1.77 billion in debt, giving a net cash position of -689.29 million or -2.89 per share.
| Cash & Cash Equivalents | 1.08B |
| Total Debt | 1.77B |
| Net Cash | -689.29M |
| Net Cash Per Share | -2.89 |
| Equity (Book Value) | 5.55B |
| Book Value Per Share | 24.90 |
| Working Capital | 981.53M |
Cash Flow
In the last 12 months, operating cash flow was -1.14 billion and capital expenditures -80.44 million, giving a free cash flow of -1.23 billion.
| Operating Cash Flow | -1.14B |
| Capital Expenditures | -80.44M |
| Free Cash Flow | -1.23B |
| FCF Per Share | -5.14 |
Margins
| Gross Margin | -17.74% |
| Operating Margin | -1,639.59% |
| Pretax Margin | -1,763.71% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TPE:6541 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.45% |
| Shareholder Yield | -33.45% |
| Earnings Yield | -10.90% |
| FCF Yield | -9.34% |
Stock Splits
The last stock split was on March 2, 2023. It was a reverse split with a ratio of 0.3335779572.
| Last Split Date | Mar 2, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.3335779572 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |